For instance, deregulated tumor suppressors miR-29b and miR-27a-5p in MM modulate anti-myeloma activity of bortezomib (BTZ) in MM cells by targeting the oncogenes SP1 and CDK5, respectively [16, 17]. The gene discussed is SP1; the disease is Miyoshi myopathy.